• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

    5/9/25 12:19:23 PM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDY alert in real time by email
    6-K 1 rdy0746_6k.htm FORM 6-K
     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    May, 2025

     

    Commission File Number 1-15182

     

    DR. REDDY’S LABORATORIES LIMITED

    (Translation of registrant’s name into English)


    8-2-337, Road No. 3, Banjara Hills

    Hyderabad, Telangana 500 034, India

    +91-40-49002900

     

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F  x                                       Form 40-F   ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

     

    Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

     

    Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

     

    Yes  ¨                                       No   x

     

    If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

     

     

     

    EXHIBITS

     

    Exhibit

    Number

     

    Description of Exhibits

     

     

     

    99.1


    Intimation dated May 9, 2025

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    DR. REDDY’S LABORATORIES LIMITED

    (Registrant)

     

     

     

     

    Date: May 9, 2025

    By:

    /s/ K Randhir Singh

     

     

    Name:

    K Randhir Singh

     

     

    Title:

    Company Secretary

     

    3
    Get the next $RDY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDY

    DatePrice TargetRatingAnalyst
    12/19/2024Buy → Neutral
    Nomura
    1/11/2024Buy → Underperform
    Jefferies
    8/29/2023Buy → Hold
    HSBC Securities
    5/18/2023Outperform → Mkt Perform
    Bernstein
    3/17/2023Neutral → Buy
    BofA Securities
    1/30/2023Underweight
    JP Morgan
    11/14/2022Neutral → Underperform
    Credit Suisse
    1/3/2022Neutral
    BofA Securities
    More analyst ratings

    $RDY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dr. Reddy's downgraded by Nomura

      Nomura downgraded Dr. Reddy's from Buy to Neutral

      12/19/24 8:23:54 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by Jefferies

      Jefferies downgraded Dr. Reddy's from Buy to Underperform

      1/11/24 8:20:29 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by HSBC Securities

      HSBC Securities downgraded Dr. Reddy's from Buy to Hold

      8/29/23 7:17:57 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

      GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

      3/27/25 11:47:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab). "The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients t

      3/18/25 8:35:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RDY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      7/1/24 6:44:13 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      5/2/22 2:44:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      2/2/21 7:05:59 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    SEC Filings

    See more

    $RDY
    Financials

    Live finance-specific insights

    See more

    $RDY
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 1:14:23 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 12:19:23 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 12:04:52 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q3 & 9MFY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

      1/23/25 12:35:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q2 & H1FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q2FY25 H1FY25   Revenues ₹ 80,162 Mn [Up: 17% YoY; 4% QoQ] ₹ 156,889 Mn [Up: 15% YoY]   Gross Margin 59.6% [Q2FY24: 58.7%; Q1FY25: 60.4%] 60.0% [H1FY24: 58.7%]   SG&A Expenses ₹ 23,007 Mn [Up: 22% YoY; 1% QoQ] ₹ 45,698 Mn [Up: 25% YoY]   R&D Expenses ₹ 7,271 Mn [9.1%

      11/5/24 9:59:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

      SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and

      2/6/25 6:35:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr

      5/28/24 9:53:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care